v3.25.2
Liquidity - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
May 09, 2024
Oct. 02, 2023
Jul. 31, 2025
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Jul. 19, 2024
Cash And Cash Equivalents [Line Items]                      
Net loss       $ (4,708,000) $ (43,773,000) $ (21,854,000) $ (21,398,000) $ (48,481,000) $ (43,252,000)    
Accumulated deficit       (500,741,000)       (500,741,000)   $ (452,260,000)  
Cash and cash equivalents       76,497,000       76,497,000   $ 87,928,000  
Marketable securities       217,300,000       217,300,000      
Principal amount of term loans       50,000,000       50,000,000      
Net cash used in operating activities               (45,360,000) (30,179,000)    
Proceeds from sale of common stock, net of costs                 $ 148,955,000    
Proceeds from exercise of common stock warrants               5,187,000      
Jefferies LLC [Member] | Maximum [Member]                      
Cash And Cash Equivalents [Line Items]                      
Aggregrate Offering Price                     $ 150,000,000
Loan And Security Agreement [Member] | Oxford [Member]                      
Cash And Cash Equivalents [Line Items]                      
Principal amount of term loans       $ 50,000,000       $ 50,000,000      
Debt instrument term               60 months      
Debt Instrument Maturity Extension Period               12 months      
Debt instrument interest period               48 months      
Debt Instrument interest rate stated percentage       5.50%       5.50%      
Debt instrument date of first required payment               Feb. 01, 2029      
Debt instrument date of final required payment               Dec. 01, 2029      
Loan And Security Agreement [Member] | Oxford [Member] | FDA Approval OF VYKATXR Tranche one [Member]                      
Cash And Cash Equivalents [Line Items]                      
Debt instrument additional borrowing amount       $ 50,000,000       $ 50,000,000      
Debt instrument date of final borrowings               Sep. 30, 2025      
Loan And Security Agreement [Member] | Oxford [Member] | FDA Approval OF VYKATXR Tranche Two [Member]                      
Cash And Cash Equivalents [Line Items]                      
Debt instrument additional borrowing amount       25,000,000       $ 25,000,000      
Debt instrument date of first borrowings               Oct. 01, 2025      
Debt instrument date of final borrowings               Sep. 30, 2026      
Loan And Security Agreement [Member] | Oxford [Member] | Contingent upon certain commercial milestones [Member]                      
Cash And Cash Equivalents [Line Items]                      
Debt instrument additional borrowing amount       25,000,000       $ 25,000,000      
Loan And Security Agreement [Member] | Oxford [Member] | Mutual Consent of Soleno and Oxford [Member]                      
Cash And Cash Equivalents [Line Items]                      
Debt instrument additional borrowing amount       $ 50,000,000       $ 50,000,000      
Underwritten Public Offering [Member]                      
Cash And Cash Equivalents [Line Items]                      
Issuance of common stock (shares) 3,450,000 3,450,000                  
Proceeds from offering after deducting underwriting discount and other estimated offering expenses $ 158,700,000 $ 69,000,000                  
Underwriter discount and other offering expenses $ 9,700,000                    
Price per unit $ 46 $ 20.00                  
Underwritten Public Offering [Member] | Subsequent Event [Member]                      
Cash And Cash Equivalents [Line Items]                      
Issuance of common stock (shares)     2,705,882                
Proceeds from offering after deducting underwriting discount and other estimated offering expenses     $ 230,000,000                
Underwriter discount and other offering expenses     $ 14,300,000                
Price per unit     $ 85